Cisplatin News and Research

RSS

Kidney treatments may be improved with new understanding of cell death mechanism

Finding how two proteins conspire to get kidney cells to self-destruct when oxygen supplies are low may one day improve dismal mortality rates for ischemic renal failure, researchers say.

23 Apr 2006

New discovery could help improve some forms of chemotherapy

The research looked at XPB helicase from an archaea, a single cell organism similar to bacteria. Helicases are enzymes that unwind or separate the strands of the nucleic acid double helix, an action that is critical to transcription and nucleotide excision repair (NER), as well as other cell processes.

11 Apr 2006

High glucose-uptake tumors can be identified with PET scans

Cervical cancers that take up a lot of blood sugar, or glucose, are more resistant to treatment than those that are less glucose-hungry, according to research at Washington University School of Medicine in St. Louis.

4 Apr 2006

Nicotine and chemotherapy not a good mix

Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.

3 Apr 2006

Light activated anticancer drug targeted to DNA using cisplatin like sub-units: Coupling light absorbers to reactive metal centers

One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects.

27 Mar 2006

New generation gold-based drugs for treating rheumatoid arthritis

Gold compounds have been used for the treatment of rheumatoid arthritis and other autoimmune diseases for more than 75 years, but until now, how the metals work has been a mystery.

27 Feb 2006

Ovarian cancer responds to aspirin and chemotherapy drug cisplatin

A new study using ovarian cancer cell lines shows promise in treating the deadly disease by combining the chemotherapy drug cisplatin with an aspirin-like compound to make recurrent cancer cells less resistant to the chemotherapy.

17 Feb 2006

Abdominal chemotherapy boosts survival in ovarian cancer patients

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone

10 Jan 2006

Intraperitoneal chemotherapy prolongs survival for women with advanced ovarian cancer

A study featured in this month's edition of Gynecologic Oncology examines the challenges associated with the administration of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy.

8 Jan 2006

Anti-cancer drugs based on platinum

Researchers at Virginia Commonwealth University's Massey Cancer Center have created a new platinum-based, anti-cancer agent able to overcome acquired drug resistance by first modifying the way it is absorbed into cancer cells and then attacking the DNA of those cancer cells.

6 Jan 2006

Delivering chemotherapy directly into the abdomen boosts survival in ovarian cancer patients

A 50-year-old method for delivering chemotherapy directly into the abdomen is making a comeback as investigators have found that it increases survival - by more than a year - in some women with advanced ovarian cancer. Results from a seven-year study of more than 400 patients nationwide are published in the New England Journal of Medicine.

6 Jan 2006

Possible new combination treatment regimen for patients with head and neck cancers who develop a second tumor

Few treatment options exist for patients with head and neck cancers who develop a second tumor or whose disease recurs in an area that has previously received radiation. Data from an international study reveal a possible new combination treatment regimen that offers a significant survival advantage for many of these patients.

18 Oct 2005

Complex chemotherapy cocktails offers pluses, minuses in advanced endometrial cancer

Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.

1 Sep 2005

Medulloblastoma irradiation may impair reading skills in young children

Irradiation therapy for the brain cancer medulloblastoma is more likely to impair IQ and reading skills of younger children than older children even if the dose of radiation is reduced, according to the results of the largest study of its kind, conducted by investigators at St. Jude Children's Research Hospital, Texas Children's Cancer Center (Houston) and Royal Children's Hospital (Melbourne, Australia).

22 Aug 2005

Compound derived from cottonseed could help improve the effectiveness of chemotherapy at treating head and neck cancer

The findings, which appear in the July issue of the journal Molecular Cancer Therapeutics, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing.

18 Jul 2005

Brief course of chemotherapy after surgery should be the new standard of care around the world

A Canadian national clinical trial has found that chemotherapy following surgery for early-stage non-small cell lung cancer significantly improves survival for the disease over just surgery alone.

27 Jun 2005

Double whammy of chemo plus surgery extends life for lung cancer patients

Recent research which has shown that chemotherapy can significantly lengthen life in many patients with lung cancer, has meant that doctors, for the first time in decades, have begun making major changes in the treatment of the disease.

23 Jun 2005

New type of inhalation chemotherapy

Pediatric cancer specialists at The Children's Hospital at Montefiore (CHAM) are investigating a new type of inhalation chemotherapy with the potential to treat children with a deadly bone cancer that has spread to their lungs.

26 May 2005

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).

16 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).